Praxis Precision Medicines to Present at Upcoming Investor Conferences in September 2025

Praxis Precision Medicines scheduled presentations at three investor conferences, showcasing their CNS disorder therapies. One-on-one meetings available.

Quiver AI Summary

Praxis Precision Medicines, Inc. announced its participation in three upcoming investor conferences, including a corporate presentation at the Baird 2025 Global Healthcare Conference on September 9, a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, and a virtual presentation at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 18. The company will also hold one-on-one meetings with investors during these events. Praxis focuses on developing therapies for central nervous system disorders related to neuronal excitation-inhibition imbalance, utilizing their unique platforms for drug discovery. Interested parties can access a replay of the webcasted event on their website for 90 days.

Potential Positives

Praxis Precision Medicines is actively engaging with investors by participating in multiple upcoming major investor conferences, which may enhance investor visibility and confidence.
The company is showcasing its clinical-stage product candidates and innovative platforms, Cerebrum™ and Solidus™, highlighting its commitment to addressing CNS disorders, which could attract interest in its therapies.
The opportunity for one-on-one meetings with management during these events allows for personalized engagement with potential investors, which may improve funding prospects.
The availability of live webcasts and replays of presentations increases access for investors, enhancing transparency and communication regarding the company's advancements and strategies.

Potential Negatives

Announcement of multiple investor conferences may indicate a need for increased investor engagement due to lack of recent significant positive news or developments.
The focus on clinical-stage programs without details on recent milestones or positive results could raise concerns about the progress and viability of their product candidates.
The lack of specific updates on clinical trials or regulatory progress might lead to skepticism about the company's future prospects.

FAQ

What investor conferences will Praxis Precision Medicines attend?

Praxis will attend Baird 2025 Global Healthcare Conference, H.C. Wainwright 27th Annual Conference, and TD Cowen's Neuropsychiatry Summit.

When will Praxis present at the Baird 2025 Global Healthcare Conference?

Praxis will present on Tuesday, September 9th, from 9:00 to 9:35 AM EDT.

How can investors access the H.C. Wainwright fireside chat?

The fireside chat will be available via a live webcast through a provided link during the event.

Will there be opportunities for one-on-one meetings with Praxis management?

Yes, interested investors can request one-on-one meetings during all investor events.

How long will the webcast replay be available on the company website?

The replay of the webcasted event will be available for 90 days on the "Events & Presentations" page.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$PRAX Hedge Fund Activity

We have seen 88 institutional investors add shares of $PRAX stock to their portfolio, and 105 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC added 1,026,969 shares (+68.2%) to their portfolio in Q2 2025, for an estimated $43,184,046
VR ADVISER, LLC removed 989,985 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $41,628,869
CAPITAL RESEARCH GLOBAL INVESTORS removed 853,746 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $35,900,019
RA CAPITAL MANAGEMENT, L.P. removed 761,955 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $28,855,235
DEERFIELD MANAGEMENT COMPANY, L.P. added 686,931 shares (+inf%) to their portfolio in Q2 2025, for an estimated $28,885,448
POINT72 ASSET MANAGEMENT, L.P. added 620,541 shares (+186.1%) to their portfolio in Q2 2025, for an estimated $26,093,749
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 619,931 shares (+inf%) to their portfolio in Q1 2025, for an estimated $23,476,786

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$PRAX Analyst Ratings

Wall Street analysts have issued reports on $PRAX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 08/05/2025
Chardan Capital issued a "Buy" rating on 07/29/2025
Needham issued a "Buy" rating on 06/12/2025
Oppenheimer issued a "Outperform" rating on 06/02/2025
Wedbush issued a "Underperform" rating on 05/05/2025

To track analyst ratings and price targets for $PRAX, check out Quiver Quantitative's $PRAX forecast page.

$PRAX Price Targets

Multiple analysts have issued price targets for $PRAX recently. We have seen 5 analysts offer price targets for $PRAX in the last 6 months, with a median target of $80.0.

Here are some recent targets:

Douglas Tsao from HC Wainwright & Co. set a target price of $115.0 on 08/05/2025
Rudy Li from Chardan Capital set a target price of $80.0 on 07/29/2025
Jay Olson from Oppenheimer set a target price of $115.0 on 07/08/2025
Ami Fadia from Needham set a target price of $80.0 on 06/12/2025
Laura Chico from Wedbush set a target price of $28.0 on 05/05/2025

Full Release

BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that Praxis’ management will be attending and presenting in three upcoming investor conferences:

Baird 2025 Global Healthcare Conference: a corporate presentation will take place on Tuesday, September 9th at 9:00-9:35am EDT at the InterContinental New York Barclay.
H.C. Wainwright 27th Annual Global Investment Conference: a fireside chat will be held on Wednesday, September 10th at 8:30am EDT at the Lotte New York Palace Hotel in New York City. A live webcast of the fireside chat will be available through this link .
TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit: a corporate presentation will take place virtually on Thursday, September 18th at 3:00-3:30pm EDT.

The Company will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

A replay of the webcasted event will also be available through the “ Events & Presentations ” page under the “ Investors + Media ” section of the company’s website for 90 days.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , Instagram , LinkedIn and Twitter/X .